



**Dr. Michael Grever (BS, 1967)**, a Pittsburgh native, entered the University of Pittsburgh in 1963. During his undergraduate studies, he pursued chemistry as a major with the intention of applying to medical school. Dr. Grever graduated from the School of Medicine at Pitt in 1971. His medical training in Internal Medicine was completed at Presbyterian University Hospital in Pittsburgh.

In 1974, Dr. Grever was inducted into the US Navy and assigned to the National Naval Medical Center in Bethesda. He completed post-doctoral training at The Ohio State University, where he joined the Faculty as an Assistant Professor. Over the subsequent eleven years, he was promoted to tenured Professor of Medicine and led a national research effort in leukemia research involving more than thirty universities. In addition, he was the principal investigator on the National Cancer Institute's Phase I Program at Ohio State.

Dr. Grever is an international leader in experimental therapy for leukemia. For the past 30 years, he dedicated his research career to developing safe, effective therapy for patients with incurable diseases. In 1989, he joined the staff at the National Cancer Institute as the Deputy-Director for the Division of Cancer Treatment, and directed the entire pre-clinical drug discovery and development program for cancer from 1990 through 1994. During his leadership period at the NCI, he directed drug discovery and development for cancer and AIDS, and introduced 19 new therapies from laboratory to patients.

Dr. Grever continues his research as a funded investigator from the National Cancer Institute, and serves on various advisory committees for the federal government involving the discovery and development of novel chemical agents to treat fatal diseases. He is currently Chairman and Professor of Medicine with an additional appointment as Professor of Pharmacology at Ohio State University.